[New indications for thalidomide?].
Tuinmann
G
G
Klinik und Poliklinik für Innere Medizin; Abteilung Onkologie, Hämatologie, Universitätsklinikum Hamburg Eppendorf. tuinmann@uke.uni-hamburg.de
Hegewisch-Becker
S
S
Hossfeld
D K
DK
D000014:Abnormalities, Drug-Induced / Q000209:etiology; D000293:Adolescent; D000328:Adult; D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D019380:Anti-HIV Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000188:drug therapy; D000075202:Contraindications; D003879:Dermatologic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004893:Erythema Nodosum / Q000188:drug therapy; D005260:Female; D006086:Graft vs Host Disease / Q000188:drug therapy; D015658:HIV Infections / Q000188:drug therapy; D006402:Hematologic Diseases / Q000188:drug therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D007231:Infant, Newborn; D007917:Leprostatic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D009101:Multiple Myeloma / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy; D011247:Pregnancy; D011817:Rabbits; D051381:Rats; D012871:Skin Diseases / Q000188:drug therapy; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D013997:Time Factors
D020533:Angiogenesis Inhibitors; D019380:Anti-HIV Agents; D000970:Antineoplastic Agents; D003879:Dermatologic Agents; D007166:Immunosuppressive Agents; D007917:Leprostatic Agents; D013792:Thalidomide
Neue Indikationen für Thalidomid?